Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?

Published:August 03, 2017DOI:
      Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by skin and internal organs fibrosis, vascular damage and positive antinuclear autoantibodies (ANAs). The classical antigenic specificities of ANAs are anti-centromere (ACA), anti-topoisomerase I antibodies (anti-topo I) and the more recently described anti-RNA polymerase III antibodies (anti-RNAPIII).


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kuwana M.
        • Kaburaki J.
        • Mimori T.
        • Tojo T.
        • Homma M.
        Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis.
        J Clin Invest. 1993; 91: 1399-1404
        • van den Hoogen F.
        • Khanna D.
        • Fransen J.
        • Johnson S.R.
        • Baron M.
        • Tyndall A.
        • et al.
        2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
        Arthritis Rheum. 2013; 65: 2737-2747
        • Sobanski V.
        • Dauchet L.
        • Lefèvre G.
        • Lambert M.
        • Morell-Dubois S.
        • Sy T.
        • et al.
        Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis.
        Arthritis Rheumatol Hoboken NJ. 2014; 66: 407-417
        • Faucher B.
        • Stein P.
        • Granel B.
        • Weiller P.-J.
        • Disdier P.
        • Serratrice J.
        • et al.
        Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.
        Eur J Intern Med. 2010; 21: 114-117
        • Parker J.C.
        • Burlingame R.W.
        • Webb T.T.
        • Bunn C.C.
        Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA.
        Rheumatol Oxf Engl. 2008; 47: 976-979
        • Emilie S.
        • Goulvestre C.
        • Bérezné A.
        • Pagnoux C.
        • Guillevin L.
        • Mouthon L.
        Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort.
        Scand J Rheumatol. 2011; 40: 404-406
        • Meyer O.
        • De Chaisemartin L.
        • Nicaise-Roland P.
        • Cabane J.
        • Tubach F.
        • Dieude P.
        • et al.
        Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study.
        J Rheumatol. 2010; 37: 125-130
        • Lazzaroni M.-G.
        • Cavazzana I.
        • Colombo E.
        • Dobrota R.
        • Hernandez J.
        • Hesselstrand R.
        • et al.
        Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening.
        J Rheumatol. 2017;
        • Codullo V.
        • Morozzi G.
        • Bardoni A.
        • Salvini R.
        • Deleonardi G.
        • De Pità O.
        • et al.
        Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis.
        Clin Exp Rheumatol. 2007; 25: 373-377
        • Yamasaki Y.
        • Honkanen-Scott M.
        • Hernandez L.
        • Ikeda K.
        • Barker T.
        • Bubb M.R.
        • et al.
        Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.
        Arthritis Rheum. 2006; 54: 3051-3056